Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up prior to trading on Thursday . The stock had previously closed at $16.90, but opened at $18.42. Ascentage Pharma Group International shares last traded at $18.2810, with a volume of 3,583 shares traded.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AAPG. BTIG Research reiterated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. B. Riley Financial initiated coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price on the stock. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Two equities research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to MarketBeat, Ascentage Pharma Group International presently has a consensus rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Stock Down 2.4%

The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. The stock has a 50 day simple moving average of $18.23 and a 200-day simple moving average of $20.98.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The firm had revenue of $22.24 million during the quarter. Analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.26 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS Group AG raised its position in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the last quarter. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International during the second quarter valued at $391,000. Finally, Citadel Advisors LLC bought a new stake in Ascentage Pharma Group International in the 3rd quarter valued at $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.